Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG (VISTA)
Open-Label, Multicenter, Ph 3 [Phase 3] Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG
Sponsor: Sesen Bio, Inc.
This PHASE3 trial investigates Bladder Cancer and is currently completed. Sesen Bio, Inc. leads this study, which shows 22 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jul 2023 — Aug 2023 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 17 earlier versions
-
Dec 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sesen Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .